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A Ab bs st tr ra ac ct t
Metabolic profiling using mass spectrometry (MS) and nuclear magnetic resonance spectroscopy
(NMR) is integral to the rapidly expanding field of metabolomics, which is making progress in
toxicology, plant science and various diseases, including cancer. In the area of oncology and
metabolic phenotyping, researchers have probed the known changes in malignant cellular
pathways using new experimental techniques to gain more insights, and others are exploiting
these same cellular pathways for therapeutic drug targets and for novel cancer biomarkers, with
the ultimate goal of translation to the clinic. Here, we discuss the challenges and opportunities in
metabolic phenotyping for discovering novel cancer biomarkers, and we assess the clinical
applicability of MS and NMR.
The National Cancer Institute recently posted a Request for
Information (RFI) proposing to bring together experts from
academia, government and industry with drug-development
skills and expertise ‘to address unmet needs in therapeutic
oncology’ [1]. This RFI calls for a cross-disciplinary and
multi-center approach to speed up the translation of new
molecular therapeutic agents directed against novel targets
to assist people with cancer. These meetings will bring
together scientists from basic research and those from the
various ‘omic’ fields. Although genomics, transcriptomics
and proteomics will undoubtedly be well represented,
metabolomics may bring the most excitement to the
meetings. Metabolomics is the comprehensive analysis of
the low-molecular-weight molecules, or metabolites, that are
the intermediates and products of metabolism. The aim of
metabolomics is to understand the underlying biochemical
processes that are altered in disease states, toxicological
progression, recovery, and so on. The potential for discovery
and utilization of novel metabolites to aid early cancer
screening and to improve diagnosis, prognosis and thera-
peutic regimens has led to an upsurge of research studies in
the field.
T Th he e   s se ea ar rc ch h   f fo or r   c ca an nc ce er r   b bi io om ma ar rk ke er rs s
The reduction of the burden of disease on society depends
on early screening and detection to enable timely thera-
peutic regimens when these therapies are likely to be most
effective. The ideal biological marker(s) for cancer risk
assessment and early detection must have high sensitivity
and specificity, be found in a biosample obtained using mini-
mally invasive procedures, and be analyzed using a high-
throughput, cost-effective assay. In lieu of early detection
biomarkers, prognostic biomarkers can empower physicians
in the selection of the most effective therapy for treating an
active tumor. The importance of studying the cellular
metabolome for the discovery of biomarkers has been shown
throughout studies conducted over the last few decades.
Tumor cells are adept at evading the host’s immune surveil-
lance, apoptosis and anti-growth checkpoints to sustain
angiogenesis and limitless replication [2]. Some of these
characteristics can be traced back to the reprogramming of
cellular bioenergetic pathways. The key pathways that
behave differently between tumor and normal cells include
the glycolysis and pentose phosphate pathways, nucleotide
and protein biosynthesis, lipid and phospholipid turnover,
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[2,3]. Essentially all pathways needed for cellular growth
and proliferation are affected, and many of these have been
targeted for drug research and development [2,4]. Several
metabolites are commonly found to be elevated in tumors,
including lactate, choline-containing compounds, nucleo-
sides, myoinositol and lipids [5]. As investigators continue to
drill down from gene expression to metabolite end products,
new hypotheses emerge concerning common metabolites.
For example, recent evidence shows that lactate may act as a
regulator of glycolysis and mitochondrial physiology, and
not simply be a waste product of glycolysis [6].
There are several reasons why metabolomics has great
potential in bringing the ‘bench closer to the bedside’. One of
the major reasons is that metabolites are already being used
in a number of diagnostic and therapeutic tests. For instance,
innate errors in fatty-acid, organic-acid and amino-acid
metabolism are measured using tandem mass spectrometry
(MS) from blood samples obtained from newborn babies [7].
Physicians also use LipoScience’s commercial nuclear
magnetic resonance spectroscopy (NMR)-based
LipoProfile® test to estimate a patient’s cardiovascular risk
by measuring the number and size of low-density lipoprotein
(LDL) particles and of the other subclasses of such particles,
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Metabolic reprogramming in tumor cells. The alteration of bioenergetic pathways in tumor cells is evident from their increased glucose uptake ( (a a) )
through glycolysis ( (b b) ), the intermediate metabolites of which are also shuttled into biosynthetic pathways (synthesis of nucleic acids from glucose
6-phosphate through the pentose phosphate pathway ( (c c) ), amino acids from glycerate 3-phosphate (not shown) and lipogenesis from pyruvate ( (d d) )) that
are necessary for cell growth and proliferation. In tumor cells, pyruvate in the mitochondria is shuttled into a truncated tricarboxylic acid cycle where it
is converted to acetyl-CoA by pyruvate dehydrogenase and combined with oxaloacetate for export into the cytosol as citrate for the synthesis of
isoprenoids, cholesterol and fatty acids. Open up and down arrows indicate upregulation and downregulation of enzymes, respectively. Enzymes
upregulated by activation of HIF-1 are in red. Abbreviations: ACL, adenosine triphosphate citrate lyase; ADP, adenosine diphosphate; ATP, adenosine
triphosphate; CA9 and CA12, carbonic anhydrases 9 and 12; CPT1A, carnitine palmitoyltransferase 1A; FASN, fatty acid synthase; G6P, glucose
6-phosphate; GLUT1,3,4, glucose transporter 1, 3 and 4; GSH, glutathione; HIF-1, hypoxia-inducible factor 1; HK1,2, hexokinase1 and 2; LAT1, L-type
amino acid transporter 1; LDH-A, lactate dehydrogenase A; MCT4, monocarboxylate transporter 4; M2-PK, pyruvate kinase isoform M2; NAD+,
nicotinamide adenine dinucleotide oxidized; NADH, nicotinamide adenine dinucleotide reduced; NADPH, nicotinamide adenine dinucleotide phosphate;
NHE1, Na+/H+ exchanger 1; OAA, oxaloacetate; OXPHOS, oxidative phosphorylation; PDH, pyruvate dehydrogenase; PDK1, pyruvate dehydrogenase
kinase 1; PFK2, phosphofructokinase 2; PGM, phosphoglycerate mutase; PI3K, phosphatidylinositol 3-kinase; PPP, pentose phosphate pathway; TLK1,
transketolase 1; VDAC, voltage-dependent anion channel. Reproduced with permission from [2].
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(d)high-density lipoprotein (HDL) and very-low-density lipo-
protein (VLDL) [8]. Just as microarray technologies have
transformed genomics and transcriptomics, new instru-
ments with higher sensitivity and throughput have had a
major impact on the metabolomics field.
A An na al ly yt ti ic ca al l   p pl la at tf fo or rm ms s   f fo or r   m me et ta ab bo ol lo om mi ic cs s: :   
M MS S   a an nd d   N NM MR R
Although MS and NMR are the main technology platforms
used for metabolic profiling, each of these technologies has its
own specific advantages and disadvantages when used in the
search for disease-specific metabolite biomarkers (Table 1).
The main advantage in using MS is its sensitivity. State-of-the-
art mass spectrometers can detect analytes routinely in the
femtomolar-attomolar range. When coupled with liquid
chromatography (LC), MS can easily detect hundreds of
individual species in a single clinical sample. Many mass
spectrometers also have high mass accuracy and can do real-
time tandem MS to identify detectable metabolites.
Unfortunately, metabolites do not provide the complex frag-
mentation patterns that peptides do, making their identifi-
cation somewhat more difficult. Quantitation, which is
critical for recognizing potentially useful biomarkers, is one
of the weaknesses of MS. There are several factors that influ-
ence the signal intensity of a compound in MS, including the
composition of the mixture in which it is located (for
example, its molecular environment). Addition of a known
amount of internal standard(s) is generally useful only for
the compound(s) it is targeted against and does not translate
to the rest of the compounds in the complex mixture, mak-
ing it impractical for metabolite biomarker discovery. Most
investigators have relied on the comparison of peak area or
intensity to measure differences in the relative abundance of
specific metabolites between samples. These measurements,
however, have suffered from a lack of accuracy and precision.
The main strengths of NMR spectroscopy are reproducibility,
the ability to quantitate compounds in mixtures and the ability
to identify unknown metabolites. Dumas et al. [9] have shown
that the analytical reproducibility of NMR is >98% and Keun
et al. [10] have observed <3% variance in identical samples
acquired at two different sites using spectrometers of two
different field strengths. Given that peak area in the NMR
spectrum relates directly to the concentration of specific
nuclei, quantitation of compounds in a complex mixture is
very precise. Once detected, various NMR pulse-sequences
can be used to help determine the structure of the molecule
that gave rise to the peak of interest; these include total
correlation spectroscopy (TOCSY), heteronuclear single
quantum coherence (HSQC) and heteronuclear multiple bond
correlation (HMBC). Another underappreciated character of
NMR is its versatility for analyzing metabolites in the liquid
state (serum, urine, and so on), in intact tissues (for example,
tumors) or in vivo. However, NMR’s major limitation is
sensitivity. Although recent technological advances in
cryogenically  cooled probe technology, higher field-strength
superconducting magnets and miniaturized radiofrequency
coils have increased sensitivity, MS is still orders of magnitude
more sensitive than NMR.
Both MS and NMR suffer in throughput for the discovery of
metabolite biomarkers, even if sample preparation methods
are not considered. To maximize metabolomic coverage, MS
relies on LC separation of the metabolites before analysis.
This need dictates that each sample will requires hours per
MS analysis. Although a single high-resolution, one-dimen-
sional  1H spectrum is obtainable in minutes, true global
profiling requires higher-dimensional data to maximize the
number of metabolites detected. Further development of
two-dimensional methodologies to increase throughput
while retaining high data resolution for global profiling is
needed. New data acquisition schemes to reduce the time
required for multidimensional data are required to make
two-dimensional NMR practical. Techniques such as non-
linear data sampling and the filter diagonalization method
show great promise [11,12]. Combining non-linear data
sampling with maximum entropy reconstruction is another
option being explored by the Wagner group at Harvard [13].
W Wh ha at t   i is s   a a   n no or rm ma al l   m me et ta ab bo ol li ic c   p pr ro of fi il le e? ?
An important consideration in any metabolomic study
aimed at identifying diagnostic or prognostic biomarkers is
that there are many modifiers of metabolic phenotype, such
as gender, age, genetics, hormonal cycle, life style, diseases
and drugs. Aside from a clear understanding of the meta-
bolic phenotype of cancer at different stages of the disease,
there is also a need to define the ‘normal’ metabolic signa-
ture as a point of comparison. Specifically, what needs to be
defined is the ‘normal range’ of inter- and intra-individual
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C Co om mp pa ar ri is so on n   o of f   M MS S   a an nd d   N NM MR R   s sp pe ec ct tr ro os sc co op py y   f fo or r   m me et ta ab bo ol lo om mi ic cs s   
Criterion Best technique
Equipment cost Neither
Maintenance cost MS
Cost per sample  Neither
Sensitivity MS
Quantitation NMR
Resolvable metabolites MS
Identification of unknown metabolites NMR
Inter-laboratory reproducibility NMR
Potential for sample bias NMR
Technical skill requirement MSmetabolite variance [14]. The range of what is considered
normal, however, can be quite large. For example, work
completed in our laboratory [15] has focused on measuring
estrogen metabolites in urine samples obtained from a sub-
population of women. This class of compounds is believed to
have an important role in the genesis and progression of
cancers of the reproductive system. Our results show that
the levels of these metabolites typically vary 10- to 100-fold
between individuals depending on their menstrual status
[15]. What is needed in the future are efforts analogous to
that underway in the Clinical Breast Care Project [16]. This
joint collaboration between the Windber Research Institute
and the Walter Reed Army Medical Center is developing a
tissue bank and database detailing the ontology of normal
breast development through the mapping of temporal
changes in gene and protein expression. Perhaps in the
future metabolic phenotyping will play a part in any such
large endeavors.
C Ca an nc ce er r   d de et te ec ct ti io on n
Several groups have aimed to exploit the metabolic differ-
ence between normal and cancerous cells to diagnose cancer.
The following select examples illustrate the use of MS and
NMR to find diagnostic or prognostic biomarkers.
P Pr ro os st ta at te e   c ca an nc ce er r   d di ia ag gn no os si is s   b by y   N NM MR R
Prostate-specific antigen (PSA) is a serine protease produced
by cells in the prostate gland that can be detected in blood
samples using monoclonal antibody assays [17,18]. The
detection of serum PSA has increased early diagnosis of
prostate cancer but has suffered from mediocre sensitivity
and specificity because other conditions, such as prostatitis
(inflammation of the prostate) and benign prostatic hyper-
plasia (BPH; enlarged prostate), can raise the level of PSA
beyond the current 4 ng/ml cutoff that is thought to indicate
cancer. Unlike other tissues, citrate is found in very high
concentrations in the prostate epithelium, where a high level
of zinc prevents the oxidation of citrate in the Krebs cycle
[19]. The citrate concentration declines in malignant cells
but remains high in BPH and normal prostate tissues. Using
1H NMR spectra of unprocessed semen and prostatic
secretions from healthy controls and patients with prostate
cancer, Kline et al. [20] were able to show that quantitation
of citrate concentration outperformed PSA for detecting
prostate cancer. Recent work by Serkova et al. [21] showed
that the absolute concentrations of citrate, myoinositol and
spermine were age-independent in human prostatic
secretions. In addition, the ratio of the concentrations of
choline plus creatine to citrate from in vivo imaging has
been shown to be a good correlation to the Gleason score,
which indicates prostate cancer aggressiveness [22].
O Ov va ar ri ia an n   c ca an nc ce er r   d di ia ag gn no os si is s   u us si in ng g   M MS S
The prevalence of ovarian cancer is low and accounts for
only about 3% of all cancers in women, but it is the most
lethal of all the gynecological malignancies [23]. Walsh et al.
[24] and Yemelyanova et al. [25] both pointed out that in
order to reduce ovarian cancer mortality, assays are needed
to screen for stage I, high-grade serous carcinomas, which
are most responsible for the high mortality rate. The five-
year survival rate of 90% for diagnosis at stage I may be
skewed because the tumors commonly detected at this stage
are non-serous tumors that have good prognosis. Screening
of women at high risk for ovarian cancer is currently
performed using ultrasound and the measurement of the
serum cancer antigen CA-125. Similarly to PSA for prostate
cancer, the CA-125 assay lacks sufficient sensitivity and
specificity. CA-125 is elevated in only 50% of stage I ovarian
tumors and in 80% of late-stage ovarian cancers [26].
In a large MS-based effort, Olivier Fiehn’s group profiled 66
invasive ovarian carcinoma tissues and 9 borderline tumors
of the ovary [27]. Principal component analysis modeling
and clustering analysis were able to distinguish 88% of the
borderline tumors from the carcinomas. Almost 300 meta-
bolites were consistently detected in 80% of the tissue
samples, of which 114 could be identified. The 51 metabolites
found to be significantly different in the two samples include
some involved in purine and pyrimidine metabolism,
glycerolipid metabolism and energy metabolism. The next
challenge is to determine which of these potential markers
survive a rigorous validation study and become useful
clinical biomarkers for invasive ovarian carcinoma.
F Fi in nd di in ng g   t th he e   m me et ta ab bo ol li ic c   s si ig gn na at tu ur re e   o of f   r ra ad di ia at ti io on n   u us si in ng g   M MS S   
a an nd d   N NM MR R
Radiation therapy, surgery and chemotherapy are three
traditional treatments for cancer. To understand why some
cancer patients respond better to ionization therapy and drug
treatment, several groups have investigated the underlying
cellular response of tumor cells to such treatments. Rainaldi
et al. [28] acquired one-dimensional 1H NMR spectra of
whole leukemia cells (HL60) to compare the apoptotic
metabolic signature induced by radiation, the antineoplastic
drug doxorubicin and heat-induced necrosis. The results
showed similar profiles for irradiation and doxorubicin-
treated leukemic cells, but the necrotic cells had different
metabolic profiles. Many of the same metabolites were found
to be depleted in the irradiation and doxorubicin-treated
cells, including reduced glutathione (GSH). In contrast, GSH
remained at low levels whereas all other metabolites showed
an increase in abundance in the necrotic cells.
Another group analyzed cell extracts from lymphoblastic
cells (TK6) treated with radiation using MS [29]. Similarly to
the above NMR study [28], they discovered GSH to be
depleted in the irradiated cells, but there were differences in
the metabolites found to be downregulated by MS [29]. This
difference may be due to the fact that the NMR group [28]
used a radiation dose that was ten times higher than the
biologically relevant ionizing radiation dose of <10.0 Gy to
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This observation highlights the fact that metabolomics,
being a young and developing field, lacks standard protocols
for sample preparation [30]. Perhaps in the future such
disparities in sample preparation will be overcome to allow
the combination and interpretation of scientific findings
obtained from different methodologies and their confirma-
tion on independent platforms.
T Th he e   o ou ut tl lo oo ok k   f fo or r   c cl li in ni ic ca al l   a ap pp pl li ic ca ab bi il li it ty y
Changes in metabolic composition are likely to be subtle in
the early stages of any disease. Many key metabolites from
different pathways have a role in tumor development, and
the ability to simultaneously detect and quantitate all these
metabolites would give a more global analysis of the state of
the tumor. Metabolomics is currently at the stage that
proteomics has occupied for the past decade: the search for
disease-specific biomarkers. It is important, however, to
look forward to the time when useful metabolite-based bio-
markers are discovered using NMR and/or MS. What will be
the role of these technologies then? Will both, either, or neither
have a role in the routine analysis of these biomarkers?
In our opinion, MS will have a greater clinical role in the
future than NMR for several reasons. The main reason is
simply that MS has historically been more widely applied for
routine clinical tests than NMR [31]. This historical ‘head
start’ has allowed more effort to be expended on developing
MS methods for clinical applications. Secondly, a clinical test
will not be required to measure as much of the entire
metabolome as it can, but simply to focus on quantifying a
single analyte or a small number of analytes. This type of
analysis is one of the major strengths of MS. Methods such
as isotope dilution (ID)-MS have been used routinely in
clinics for decades. A recent study compared the accuracy and
precision of three methodologies - enzyme-linked immuno-
sorbent assay (ELISA), LC with fluorescence detection and
LC with ID-MS - to analyze aflatoxin-albumin adducts in
human serum as a measure of aflatoxin exposure [32]. Afla-
toxins have been shown to be carcinogenic in humans and
animals and are linked to an increased risk of hepatocellular
carcinoma. The ID-MS method not only showed the lowest
standard deviation, but also the greatest sensitivity. ID-MS
has also shown exquisite precision and sensitivity in a
variety of clinical tests.
Currently, most clinical MS assays are conducted in refer-
ence laboratories and not within hospital-based clinical
laboratories. This fact is a result of the expertise required to
prepare and analyze samples using MS and to interpret the
results. As the technology becomes simpler to use and the
number of scientists familiar with this technology continues
to increase, the use of MS-based tests within the hospital
clinic will certainly expand. Clinical NMR spectroscopy is
currently more focused on the in vivo imaging area, and
although its role in metabolite biomarker discovery will
continue to increase, it faces more obstacles than MS before
becoming a routine clinical tool. Although LipoScience is
currently working on developing a fully automated clinical
NMR analyzer, in general the lack of NMR spectrometers
within clinical laboratories and NMR’s low intrinsic
sensitivity contribute to the greater challenge of making this
technology routine when compared with MS.
Advances in MS and NMR instrumentation will also be
crucial in bringing these technologies from the bench to the
bedside. For MS, this will require simplification of the
entire analytical method, starting with sample preparation
and continuing through to the final data analysis and
presentation. The major NMR instrumentation break-
throughs needed can be best illustrated by a recent article
describing a miniaturized diagnostic magnetic resonance
(DMR) system [33]. This chip-based DMR system uses
multichannel detection for the analysis of unprocessed
biological samples approaching sensitivity limits of 10-12 M.
This multichannel miniaturized NMR has been shown to be
able to detect bacteria, profile circulating cells and identify
biomarkers in sera obtained from cancer patients. Chip-
based systems, such as the DMR, may provide the low-cost,
high-throughput platforms necessary for point-of-care
translational medicine.
The ability to translate biomarkers quickly for cancer diag-
nosis, prognosis and risk assessment from their discovery to
their application within the clinic would have an enormous
impact on public health. The entire concept of ‘bench-to-
bedside’ has been discussed for several years and has been
used in both genomics and proteomics. This concept is now
firmly entrenched within the field of metabolomics as well.
Metabolomics has the opportunity to learn from the issues
that have primarily plagued proteomics investigators over
the past few years. One of these issues is standardization.
The ability to compare results from various labs working on
similar problems could certainly shorten the time for bio-
marker discovery. Fortunately, the Metabolomics Society has
organized a Chemical Analysis Working Group to develop
standards for metabolomic analysis [34]. Adherence to these
standards will assist in inter-laboratory data comparison
and hopefully will also expedite the finding of clinically
relevant metabolite biomarkers.
A Ab bb br re ev vi ia at ti io on ns s
BPH, benign prostatic hyperplasia; DMR, diagnostic magnetic
resonance; ELISA, enzyme-linked immunosorbent assay;
GSH, reduced glutathione; HDL, high-density lipoprotein;
HMBC, heteronuclear multiple bond correlation; HSQC,
heteronuclear single quantum coherence; ID-MS, isotope
dilution mass spectrometry; LC, liquid chromatography; LDL,
low-density lipoprotein; MS, mass spectrometry; NMR,
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